Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This medication helps improve lung function and oxygenation, making it a critical treatment in neonatal care.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed and lack sufficient surfactant, a substance that keeps the air sacs in the lungs open. By replacing the missing surfactant, Curosurf helps to improve breathing and reduce the need for mechanical ventilation. It is administered directly into the lungs through a procedure known as endotracheal instillation.

Curosurf works by coating the inner surface of the lungs, reducing surface tension and preventing the collapse of the air sacs. This action helps to improve lung compliance and gas exchange, making it easier for the infant to breathe. The effects of Curosurf are typically observed shortly after administration, providing immediate relief from respiratory distress.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. It is important to monitor the infant closely for any signs of adverse reactions. Proper handling and storage of the medication are crucial to maintain its effectiveness. Always follow the guidelines provided by the manufacturer and healthcare provider.

Curosurf is generally well-tolerated, but it is important to inform your healthcare provider about any other medications the infant is taking. Certain medications or medical conditions may interact with Curosurf, so it is essential to discuss all relevant factors with a healthcare professional before administration.